Prognostic Value of CD1B in Localised Prostate Cancer

Bibliographic Data

ID15515638
AuthorsCheng‐Hsueh Lee (Kaohsiung Medical University), Cheng-Hsueh Lee (Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan), Lih‐Chyang Chen (Mackay Medical College), Lih-Chyang Chen (0000-0002-2519-5065, Mackay Medical College), Chia‐Cheng Yu (0000-0002-2620-1914, National Yang Ming Chiao Tung University), Chia-Cheng Yu (Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan), Wen‐Hsin Lin (0000-0002-7216-1626, China Medical University), Victor C Lin (0000-0003-0075-7014, I-Shou University), Chao‐Yuan Huang (0000-0002-9322-6062, National Taiwan University Hospital), Chao-Yuan Huang (Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan), Te‐Ling Lu (0000-0003-1408-6004, China Medical University), Shu‐Pin Huang (0000-0003-2968-6125, Kaohsiung Medical University Chung-Ho Memorial Hospital, corresponding author), Shu-Pin Huang (Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan), Bo‐Ying Bao (0000-0001-5510-6513, China Medical University Hospital, corresponding author)
Year2019
Volume16
Issue23
Pages4723-4723
Publication date2019-11-27
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph16234723
PMID31783478
OpenAlexW2989945352
LanguageEN
References cited32

Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification

Antigen · Biochemical recurrence · Biology · breakpoint cluster region · Cancer · Confidence interval · Gene · Hazard ratio · Human leukocyte antigen · Population · Prostate · Prostate cancer · Prostate-specific antigen · Prostatectomy · Immune Cell Function and Interaction · Immunotherapy and Immune Responses · Medicine · Prostate Cancer Treatment and Research · Cancer Research · Genetics · Immunology · Internal Medicine · Oncology

Tools

Open DOISci-HubOpen Access